title: The next generation: new chemotherapy agents for the 1990s.
abstract: The progress in cancer chemotherapy since the 1940s has been tremendous with over 40 cytotoxic agents, excluding hormones, that have undergone clinical trials and been approved by the Food and Drug Administration (FDA). Preclinical drug development and clinical trials have made this progress possible. Several new agents that are either undergoing clinical trials or have recently been approved by the FDA include idarubicin, ICRF-187, piroxantrone, all-trans-retinoic acid, fludarabine phosphate, taxol, and suramin.
authors.affiliation: Department of Nursing, Warren Grant Manguson Clinical Center, National Institutes of Health, Bethesda, MD 20892.
authors.forename: A
authors.initials: A
authors.lastname: Galassi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000639:trends; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing; D009859:Oncology Nursing / Q000379:methods; D012380:Role
chemical_list: D000970:Antineoplastic Agents